C4 Therapeutics (CCCC) Cash & Current Investments (2019 - 2026)

C4 Therapeutics has reported Cash & Current Investments for 8 years, with the latest figure at $235.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 9.57% year-over-year to $235.7 million; the trailing twelve-month figure through Mar 2026 stood at $235.7 million (up 9.57% YoY), and the FY2025 full-year result was $248.5 million, up 1.48% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $235.7 million, down from $248.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $313.7 million in Q3 2022, with the low at $191.9 million in Q3 2025.
• Average Cash & Current Investments over 5 years is $254.4 million, with a median of $255.6 million recorded in 2024.
• Year-over-year, Cash & Current Investments sank 33.94% in 2022 and rose 18.04% in 2024.
• Tracing CCCC's Cash & Current Investments over 5 years: stood at $276.2 million in 2022, then dropped by 8.14% to $253.7 million in 2023, then dropped by 3.46% to $244.9 million in 2024, then grew by 1.48% to $248.5 million in 2025, then slipped by 5.18% to $235.7 million in 2026.
• The last three Cash & Current Investments figures came in at $235.7 million (Q1 2026), $248.5 million (Q4 2025), and $191.9 million (Q3 2025), per Business Quant data.

Peer Comparison